Published in Autoimmun Rev on December 06, 2012
Autoimmunity contributes to nociceptive sensitization in a mouse model of complex regional pain syndrome. Pain (2014) 0.90
Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. J Pain Res (2013) 0.85
The prevalence of autoantibodies in complex regional pain syndrome type I. Mediators Inflamm (2015) 0.84
Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data. EBioMedicine (2015) 0.84
Acute and chronic phases of complex regional pain syndrome in mice are accompanied by distinct transcriptional changes in the spinal cord. Mol Pain (2013) 0.83
Plasma amino acids changes in complex regional pain syndrome. Pain Res Treat (2013) 0.82
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. PLoS One (2015) 0.81
New Concepts in Complex Regional Pain Syndrome. Hand Clin (2016) 0.80
Immunotherapy Prospects for Painful Small-fiber Sensory Neuropathies and Ganglionopathies. Neurotherapeutics (2016) 0.80
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight (2016) 0.77
Phenoxybenzamine in complex regional pain syndrome: potential role and novel mechanisms. Anesthesiol Res Pract (2013) 0.77
Spontaneous onset of complex regional pain syndrome Type I in a woman infected with Bartonella koehlerae. Med Microbiol Immunol (2013) 0.77
The inflammasome as a target for pain therapy. Br J Anaesth (2016) 0.76
Complex regional pain syndrome in a competitive athlete and regional osteoporosis assessed by dual-energy X-ray absorptiometry: a case report. J Med Case Rep (2014) 0.75
Immune activation and autoimmunity in chronic pain conditions and response to immunoglobulin G. Clin Exp Immunol (2014) 0.75
Elevated Plasma Levels of sIL-2R in Complex Regional Pain Syndrome: A Pathogenic Role for T-Lymphocytes? Mediators Inflamm (2017) 0.75
Successful Treatment of Lower Limb Complex Regional Pain Syndrome following Three Weeks of Hyperbaric Oxygen Therapy. Pain Res Manag (2016) 0.75
7th International Immunoglobulin Conference: Immunomodulation. Clin Exp Immunol (2014) 0.75
Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain (2011) 1.89
Aggravation of infarct formation by brain swelling in a large territorial stroke: a target for neuroprotection? J Neurosurg (2008) 1.53
Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. J Neurol (2007) 1.20
Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett (2005) 1.00
Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen. Pain (2009) 0.91
Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome. JAMA Neurol (2013) 0.90
Midline-shift corresponds to the amount of brain edema early after hemispheric stroke--an MRI study in rats. J Neurosurg Anesthesiol (2007) 0.88
RNase therapy assessed by magnetic resonance imaging reduces cerebral edema and infarction size in acute stroke. Curr Neurovasc Res (2009) 0.88
Cranial venous outflow under lower body positive and negative pressure conditions and head-up and -down tilts. J Neuroimaging (2008) 0.87
Intravenous immunoglobulin reduces infarct volume but not edema formation in acute stroke. Neuroimmunomodulation (2009) 0.87
Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol (2005) 0.83
Evaluation of methods to predict early long-term neurobehavioral outcome after coronary artery bypass grafting. Am J Cardiol (2010) 0.82
Biomarkers of inflammation and endothelial dysfunction in stroke with and without sleep apnea. Cerebrovasc Dis (2012) 0.82
CRMP-5-autoantibodies in testicular cancer associated with limbic encephalitis and choreiform dyskinesias. Eur Neurol (2007) 0.80
Reversible MR imaging abnormalities following cerebral venous thrombosis. AJNR Am J Neuroradiol (2005) 0.80
Influence of statins on MHC class I expression. Ann N Y Acad Sci (2009) 0.79
Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol (2004) 0.78
Increased seroprevalence of parvovirus B 19 IgG in complex regional pain syndrome is not associated with antiendothelial autoimmunity. Eur J Pain (2006) 0.78
SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev (2009) 0.77
Skeletal muscle cell MHC I expression: implications for statin-induced myopathy. Muscle Nerve (2010) 0.77
Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action? J Neuroimmunol (2013) 0.77
Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity. J Leukoc Biol (2013) 0.76
Tumour-induced anti-Hu autoimmunity in mice--a step towards animal models of paraneoplastic disease. J Neuroimmunol (2009) 0.75